Biochem/physiol Actions
PAK7 (p21 protein (Cdc42/Rac)-activated kinase 7) belongs to the group-2 PAKs and can activate JNK (Jun N-terminus kinase). It contain an amino-terminal CDC42 (cell division cycle 42)/RAC (AKT1, v-akt murine thymoma viral oncogene homolog 1) interactive domain and a carboxyl terminal kinase domain. It plays an important role in outgrowth of neuron cells and synaptic vesicle trafficking. In mice, absence of PAK7 and PAK6 causes learning and locomotion defects. It is mainly expressed in brain. However, it is also considered as an oncogene because of its expression in colorectal, esophageal and gastric cancers.
Physical form
Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.2 5mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.
Legal Information
PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany
| recombinant | expressed in baculovirus infected Sf9 cells |
| Quality Level | 200 |
| product line | PRECISIO® Kinase |
| assay | ≥70% (SDS-PAGE) |
| form | buffered aqueous glycerol solution |
| specific activity | 47-63 nmol/min·mg |
| mol wt | ~130 kDa |
| UniProt accession no. | Q9P286 |
| relevant disease(s) | cancer |
| shipped in | dry ice |
| storage temp. | −70°C |
| Gene Information | human ... PAK7(57144) |
